\n<\/p>\n
Peptides, the same class of wonder molecule behind GLP-1 drugs like Ozempic, could soon be easier to get your hands on. A federal advisory panel voted 8-6 to recommend easing restrictions on peptides like BPC-157 and TB-500, chemicals popular with wellness influencers like Joe Rogan and telehealth clinics, the AP reports<\/a>. Unlike Ozempic, these compounds are not FDA-approved medications.<\/p>\n The vote doesn\u2019t immediately clear the way for peptides to be legal, but it sends a signal. Health Secretary Robert F. Kennedy Jr. has called himself a \u201cbig fan\u201d of peptides and already removed some from the FDA\u2019s high-risk list earlier this year. Panel members with ties to the peptide industry, several added shortly before the vote, largely supported easing access, while some scientists were less enthusiastic. <\/p>\n \u201cThis is really alarming,\u201d said Rita Jew, a pharmacist and president of the Institute for Safe Medication Practices, describing the marketplace as a \u201cWild West\u201d of unproven, unregulated drugs. The FDA is expected to make its final call after reviewing votes and public comments from this week\u2019s hearings.<\/p>\n<\/p><\/div>\n Peptides, the same class of wonder molecule behind GLP-1 drugs like Ozempic, could soon be easier to get your hands on. A federal advisory panel voted 8-6 to recommend easing restrictions on peptides like BPC-157 and TB-500, chemicals popular with wellness influencers like Joe Rogan and telehealth clinics, the AP reports<\/a>. Unlike Ozempic, these compounds are not FDA-approved medications.<\/p>\n The vote doesn\u2019t immediately clear the way for peptides to be legal, but it sends a signal. Health Secretary Robert F. Kennedy Jr. has called himself a \u201cbig fan\u201d of peptides and already removed some from the FDA\u2019s high-risk list earlier this year. Panel members with ties to the peptide industry, several added shortly before the vote, largely supported easing access, while some scientists were less enthusiastic. <\/p>\n \u201cThis is really alarming,\u201d said Rita Jew, a pharmacist and president of the Institute for Safe Medication Practices, describing the marketplace as a \u201cWild West\u201d of unproven, unregulated drugs. The FDA is expected to make its final call after reviewing votes and public comments from this week\u2019s hearings.<\/p>\n<\/p><\/div>\n